278 related articles for article (PubMed ID: 18226465)
21. Valproic acid for the treatment of myeloid malignancies.
Kuendgen A; Gattermann N
Cancer; 2007 Sep; 110(5):943-54. PubMed ID: 17647267
[TBL] [Abstract][Full Text] [Related]
22. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic biomarkers for human cancer: the time is now.
Mulero-Navarro S; Esteller M
Crit Rev Oncol Hematol; 2008 Oct; 68(1):1-11. PubMed ID: 18430583
[TBL] [Abstract][Full Text] [Related]
24. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective.
Awada A; Mano M; Hendlisz A; Piccart M
Expert Rev Anticancer Ther; 2004 Feb; 4(1):53-60. PubMed ID: 14748657
[TBL] [Abstract][Full Text] [Related]
25. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
26. Development of curcumin as an epigenetic agent.
Fu S; Kurzrock R
Cancer; 2010 Oct; 116(20):4670-6. PubMed ID: 20597137
[TBL] [Abstract][Full Text] [Related]
27. Valproic acid induces polarization, neuronal-like differentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression.
Benítez JA; Arregui L; Cabrera G; Segovia J
Neuroscience; 2008 Oct; 156(4):911-20. PubMed ID: 18771712
[TBL] [Abstract][Full Text] [Related]
28. New perspectives of valproic acid in clinical practice.
Činčárová L; Zdráhal Z; Fajkus J
Expert Opin Investig Drugs; 2013 Dec; 22(12):1535-47. PubMed ID: 24160174
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic deregulation of DNA repair and its potential for therapy.
Hegi ME; Sciuscio D; Murat A; Levivier M; Stupp R
Clin Cancer Res; 2009 Aug; 15(16):5026-31. PubMed ID: 19671858
[TBL] [Abstract][Full Text] [Related]
30. Targeting epigenetic changes in acute myeloid leukemia.
Blum W; Marcucci G
Clin Adv Hematol Oncol; 2005 Nov; 3(11):855-65, 882. PubMed ID: 16491631
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic disregulation induces cell growth retardation in primary cultured glial cells.
Nagai K; Natori T; Nishino T; Kodaira F
J Biosci Bioeng; 2008 May; 105(5):470-5. PubMed ID: 18558336
[TBL] [Abstract][Full Text] [Related]
32. Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
Kim TH; Yoo YH; Kang DY; Suh H; Park MK; Park KJ; Kim SH
Int J Oncol; 2009 May; 34(5):1353-62. PubMed ID: 19360347
[TBL] [Abstract][Full Text] [Related]
33. Rational combinations using HDAC inhibitors.
Bots M; Johnstone RW
Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy.
Sigalotti L; Coral S; Fratta E; Lamaj E; Danielli R; Di Giacomo AM; Altomonte M; Maio M
Semin Oncol; 2005 Oct; 32(5):473-8. PubMed ID: 16210088
[TBL] [Abstract][Full Text] [Related]
35. D-Serine exposure resulted in gene expression changes implicated in neurodegenerative disorders and neuronal dysfunction in male Fischer 344 rats.
Davidson ME; Kerepesi LA; Soto A; Chan VT
Arch Toxicol; 2009 Aug; 83(8):747-62. PubMed ID: 19212759
[TBL] [Abstract][Full Text] [Related]
36. [New therapeutic approaches for solid tumors: histone deacetylase, methyltransferase and proteasome inhibitors].
Becker JC; Ugurel S; Bröcker EB; Schrama D; Houben R
J Dtsch Dermatol Ges; 2006 Feb; 4(2):108-13. PubMed ID: 16503937
[TBL] [Abstract][Full Text] [Related]
37. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
Dal Lago L; D'Hondt V; Awada A
Oncologist; 2008 Aug; 13(8):845-58. PubMed ID: 18695262
[TBL] [Abstract][Full Text] [Related]
38. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
Flis S; Gnyszka A; Spławiński J
Biochem Biophys Res Commun; 2009 Sep; 387(2):336-41. PubMed ID: 19596269
[TBL] [Abstract][Full Text] [Related]
39. Rational targeting of Notch signaling in cancer.
Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
[TBL] [Abstract][Full Text] [Related]
40. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
